Results: 5

1.
Figure 2

Figure 2. From: Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Incidence of laboratory-confirmed clinical influenza in elderly nursing home residents who received 6 weeks of seasonal prophylaxis with oseltamivir or placebo. Figure derived from data in Peters et al.46

Regina Dutkowski. J Antimicrob Chemother. 2010 April;65(Suppl 2):ii11-ii24.
2.
Figure 3

Figure 3. From: Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Total influenza A viruses subtyped as H1N1 (n = 5984), and number of oseltamivir-resistant and oseltamivir-susceptible H1N1 viruses for which oseltamivir susceptibility was determined (n = 2949), by week, Europe, winter 2007–08. Reproduced from Meijer et al.69 with permission.

Regina Dutkowski. J Antimicrob Chemother. 2010 April;65(Suppl 2):ii11-ii24.
3.
Figure 1

Figure 1. From: Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Incidence of laboratory-confirmed influenza infection in household contacts without influenza at baseline who did or did not receive oseltamivir post-exposure prophylaxis (commenced within 48 h of symptom onset). Figure derived from data in Hayden et al.44

Regina Dutkowski. J Antimicrob Chemother. 2010 April;65(Suppl 2):ii11-ii24.
4.
Figure 4

Figure 4. From: Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

(a) Mean (±SD) concentration–time profile for oseltamivir in plasma after a single oral dose of 150 mg of oseltamivir phosphate in Caucasian (n = 4) and Japanese (n = 4) subjects and the overall population (n = 8). (b) Mean (±SD) concentration–time profile for oseltamivir in CSF after a single oral dose of 150 mg of oseltamivir phosphate in Caucasian (n = 4) and Japanese (n = 4) subjects and the overall population (n = 8). Reproduced from Jhee et al.91 with permission.

Regina Dutkowski. J Antimicrob Chemother. 2010 April;65(Suppl 2):ii11-ii24.
5.
Figure 5

Figure 5. From: Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

(a) Mean (±SD) concentration–time profile for oseltamivir carboxylate in plasma after a single oral dose of 150 mg of oseltamivir phosphate in Caucasian (n = 4) and Japanese (n = 4) subjects and the overall population (n = 8). (b) Mean (±SD) concentration–time profile for oseltamivir carboxylate in CSF after a single oral dose of 150 mg of oseltamivir phosphate in Caucasian (n = 4) and Japanese (n = 4) subjects and the overall population (n = 8). Reproduced from Jhee et al.91 with permission.

Regina Dutkowski. J Antimicrob Chemother. 2010 April;65(Suppl 2):ii11-ii24.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk